PATANASE
LOE ApproachingNDANASALSPRAY, METERED
Approved
Apr 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
PATANASE by Novartis is 1 -receptor antagonist. First approved in 2008.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PATANASE is olopatadine, a selective H1-receptor antagonist nasal spray approved in 2008 for allergic and vasomotor rhinitis. It works by blocking histamine-mediated allergic responses at the nasal mucosal level. This small-molecule treatment provides targeted, local symptom relief for chronic rhinitis sufferers.
$0.04MPart D
LOE ApproachingDeclining
Declining Part D utilization and LOE-approaching status signal a contracting commercial footprint; brand team likely consolidating or shifting focus to line extensions.
Mechanism of Action
1 -receptor antagonist. The antihistaminic activity of olopatadine has been documented in isolated tissues, animal models, and humans.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis
Started Nov 2008
1,260 enrolled
Perennial Allergic Rhinitis
Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of Age
Started Oct 2008
132 enrolled
Allergic Rhinitis
Career Relevance
PATANASE roles are limited and declining; working on this product offers exposure to mature-stage brand management and field execution but limited growth opportunity. Sponsoring organization (Novartis) stability provides job security, but the LOE-approaching lifecycle suggests career progression may require lateral movement to growth-stage assets within the portfolio.
Brand Manager
Worked on PATANASE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.